Clinical trials: Moderate Respiratory Distress
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
ARDS (Acute Respiratory Distress Syndrome)
Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
This Phase 1/2A, randomized, double-blind study will evaluate the safety, tolerability, and pharmacokinetics (PK) of HT31-1 (hCitH3-mAb) in healthy adult volunteers and in patients with mild-to-moderate acute respiratory distress…
- Trial name
- NCT07449572
- Testing
- HT31-1, Saline (0.9%, sterile, for infusion)
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HTIC, Inc
Acute Respiratory Distress Syndrome
Effect of APRV and LTV on Lung Ventilation and Perfusion in Patients With Moderate-to-severe ARDS
Low tidal volume ventilation (LTV) has been proposed and widely used in patients with acute respiratory distress syndrome (ARDS) to prevent ventilator-induced lung injury (VILI) and mitigate its effects.
- Trial name
- NCT05767125
- Testing
- APRV, LTV
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Respiratory Distress, Newborn
Effectiveness of HVNI in Preterm Infants With Moderate Respiratory Distress
Neonatal respiratory distress is a common problem in preterm infants. The application of CPAP is widely used in neonatal units as a primary mode of respiratory support for respiratory distress.
- Trial name
- NCT06436222
- Testing
- HVNI
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Acute Respiratory Distress Syndrome (ARDS)
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.
- Trial name
- NCT05938036
- Testing
- ALT-100 mAb
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Aqualung Therapeutics Corp.